These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 35526927)

  • 41. Vitiligo- and melanoma-associated hypopigmentation: a similar appearance but a different mechanism.
    Merimsky O; Shoenfeld Y; Yecheskel G; Chaitchik S; Azizi E; Fishman P
    Cancer Immunol Immunother; 1994 Jun; 38(6):411-6. PubMed ID: 8205563
    [TBL] [Abstract][Full Text] [Related]  

  • 42. A rational approach to the treatment of vitiligo and other hypomelanoses.
    Hercogová J; Buggiani G; Prignano F; Lotti T
    Dermatol Clin; 2007 Jul; 25(3):383-92, ix. PubMed ID: 17662904
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Guideline for the diagnosis and management of vitiligo.
    Gawkrodger DJ; Ormerod AD; Shaw L; Mauri-Sole I; Whitton ME; Watts MJ; Anstey AV; Ingham J; Young K; ; ; ;
    Br J Dermatol; 2008 Nov; 159(5):1051-76. PubMed ID: 19036036
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Therapeutic interventions to lessen the psychosocial effect of vitiligo in children: A review.
    Cadmus SD; Lundgren AD; Ahmed AM
    Pediatr Dermatol; 2018 Jul; 35(4):441-447. PubMed ID: 29766546
    [TBL] [Abstract][Full Text] [Related]  

  • 45. [Vitiligo as an aesthetic problem. Noninvasive therapeutic methods in vitiligo].
    Popko M; Kacalak-Rzepka A; Bielecka-Grzela S; Wesołowska J; Klimowicz A; Maleszka R
    Ann Acad Med Stetin; 2011; 57(3):23-7. PubMed ID: 23383544
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Vitiligo-like depigmentation in patients receiving programmed cell death-1 inhibitor reflects active vitiligo.
    Fukuda K; Harris JE
    J Am Acad Dermatol; 2018 Jan; 78(1):e15-e16. PubMed ID: 29241799
    [No Abstract]   [Full Text] [Related]  

  • 47. [Dermatology, cosmetic and well-being].
    Battie C; Verschoore M
    Ann Dermatol Venereol; 2011; 138(4):294-301. PubMed ID: 21497256
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Possible involvement of CCR4+ CD8+ T cells and elevated plasma CCL22 and CCL17 in patients with rhododenol-induced leukoderma.
    Nishioka M; Tanemura A; Yang L; Tanaka A; Arase N; Katayama I
    J Dermatol Sci; 2015 Mar; 77(3):188-90. PubMed ID: 25766765
    [No Abstract]   [Full Text] [Related]  

  • 49. Vitiligo-like lesions in patients receiving anti-programmed cell death-1 therapies are distinct from spontaneously occurring active vitiligo.
    Boniface K; Dutriaux C; Prey S; Taieb A; Seneschal J
    J Am Acad Dermatol; 2018 Jan; 78(1):e17-e18. PubMed ID: 29241800
    [No Abstract]   [Full Text] [Related]  

  • 50. Dissociated depigmentation in vitiligo; significance and therapeutic implications.
    PEGUM JS
    Br J Dermatol; 1955 Oct; 67(10):348-50. PubMed ID: 13260554
    [No Abstract]   [Full Text] [Related]  

  • 51. The Double Strike Hypothesis of the vitiligo pathomechanism: new approaches to vitiligo and melanoma.
    Michelsen D
    Med Hypotheses; 2010 Jan; 74(1):67-70. PubMed ID: 19748188
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Camouflaging vitiligo with dihydroxyacetone.
    Hsu S
    Dermatol Online J; 2008 Aug; 14(8):23. PubMed ID: 19061581
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Treatment with Modified Heat Shock Protein Repigments Vitiligo Lesions in Sinclair Swine.
    Frisoli ML; Harris JE
    J Invest Dermatol; 2018 Dec; 138(12):2505-2506. PubMed ID: 30466536
    [TBL] [Abstract][Full Text] [Related]  

  • 54. [Unilateral systematized vitiligo or achromic nevus].
    CARO-PATON T
    Actas Dermosifiliogr; 1950 May; 41(8):717-23. PubMed ID: 14770946
    [No Abstract]   [Full Text] [Related]  

  • 55. The effectiveness of therapeutic interventions on quality of life for vitiligo patients: a systematic review.
    Chan MF; Chua TL
    Int J Nurs Pract; 2012 Aug; 18(4):396-405. PubMed ID: 22845640
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Leukoderma centrifugum acquisitum and vitiligo.
    KANEE B
    AMA Arch Derm; 1957 Jun; 75(6):873-4. PubMed ID: 13423897
    [No Abstract]   [Full Text] [Related]  

  • 57. Possible mechanisms of hypopigmentation in lichen sclerosus.
    Carlson JA; Grabowski R; Mu XC; Del Rosario A; Malfetano J; Slominski A
    Am J Dermatopathol; 2002 Apr; 24(2):97-107. PubMed ID: 11979069
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Possible mechanisms in the induction of vitiligo-like hypopigmentation by topical imiquimod.
    Mashiah J; Brenner S
    Clin Exp Dermatol; 2008 Jan; 33(1):74-6. PubMed ID: 17979992
    [TBL] [Abstract][Full Text] [Related]  

  • 59. [The 308 nm Excimer laser : Treatment of vitiligo and hypopigmentation].
    Fritz K; Salavastru C
    Hautarzt; 2018 Jan; 69(1):44-47. PubMed ID: 29294169
    [TBL] [Abstract][Full Text] [Related]  

  • 60. An immune pathological and ultrastructural skin analysis for rhododenol-induced leukoderma patients.
    Tanemura A; Yang L; Yang F; Nagata Y; Wataya-Kaneda M; Fukai K; Tsuruta D; Ohe R; Yamakawa M; Suzuki T; Katayama I
    J Dermatol Sci; 2015 Mar; 77(3):185-8. PubMed ID: 25676426
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.